Research guide
Semax
Semax is a synthetic peptide analog of the ACTH(4-10) fragment (a segment of adrenocorticotropic hormone) developed in Russia in the 1980s at the Institute of Molecular Genetics in Moscow. It is designed to provide neuroprotective and cognitive-enhancing effects without the hormonal activity of full ACTH. The peptide was approved by the Russian Ministry of Health in 1994 for cerebrovascular and cognitive indications. Semax has been used in Russian clinical settings for over 30 years for stroke recovery, cognitive disorders, and optic nerve conditions. The compound is administered intranasally or intravenously in research contexts. This is a research-use-only compound under FDA review for potential approval; it is not currently FDA-approved in the United States. For research purposes only; not for human consumption or medical treatment.
What the research shows
Semax upregulates both BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor) simultaneously—a dual neurotrophic effect uncommon among nootropic compounds. A single dose of Semax triples hippocampal BDNF mRNA expression, suggesting broad cognitive benefits through effects on hippocampal function and synaptic plasticity.
positive · Multiple research reviews and Russian clinical research ↗
Extensive research demonstrates Semax produces significant improvements in attention span, memory formation, information processing speed, and learning capacity across multiple animal models and human clinical studies. Long-term beneficial action on work efficiency of operators was observed after intranasal administration of 0.25-1.0 mg following single dose.
positive · Russian clinical research and neurotrophic studies ↗
In a rat model of cerebral ischemia-reperfusion, Semax suppressed inflammatory and cell death processes through region-specific protein expression modulation: inhibiting JNK activation, activating phosphorylated CREB, and downregulating MMP-9 and c-Fos in cortical tissue.
positive · Institute of Molecular Genetics and affiliated Russian institutions, MDPI Molecules (2022) ↗
A preliminary trial in a limited cohort of Alzheimer's disease patients showed that Semax can potentially be used to prevent and treat Alzheimer's disease, though further investigation is needed before broader clinical application.
While Semax has a long track record in Russia with a favorable safety profile and mild reported side effects (nasal irritation, headache, occasional overstimulation), controlled safety data meeting Western standards is absent. Carcinogenicity, mutagenicity, and reproductive toxicity studies have not been formally conducted.
negative · Regulatory assessment and research review comparison ↗
Western evidence remains largely preclinical; human data derives mostly from Russian-language clinical publications with limited independent peer review in Western journals. As of April 2026, Semax is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026.
mixed · FDA regulatory update and research status assessment ↗
What experts say — both sides
Demonstrated Semax suppresses inflammatory and cell death processes and activates recovery mechanisms in cerebral ischemia models through transcriptomic and protein expression analysis. Conducted genome-wide RNA-Seq showing Semax suppresses inflammatory genes and activates neurotransmitter genes, supporting neuroprotective mechanisms.
Institute of Molecular Genetics research publications, MDPI Molecules (2022) ↗
Provides detailed mechanistic guidance on Semax and related peptides (Selank), noting dual BDNF/NGF upregulation and applications in stroke recovery, cognitive disorders, PTSD, anxiety, and depression. Acknowledges Russian clinical approval and 30+ year track record but emphasizes need for Western-standard validation.
As of April 2026, Semax is scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 24, 2026, indicating recognition of potential therapeutic merit but acknowledgment that Western regulatory approval is not yet established. Status remains under review for potential compounding use.
Safety & legal status
Semax is NOT FDA-approved in the United States as of June 2026. The compound was approved by the Russian Ministry of Health in 1994 for cerebrovascular and cognitive indications and has been used in Russian clinical settings for over 30 years with an established safety profile. Reported side effects in Russian clinical use are mild and include nasal irritation, headache, and occasional overstimulation; no dependence, withdrawal, or abuse potential has been documented. However, controlled safety data meeting Western regulatory standards is absent. Carcinogenicity, mutagenicity, and reproductive toxicity studies have not been formally conducted. As of April 2026, Semax is scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026, indicating potential regulatory reconsideration but no current approval status. Western regulatory bodies have not yet accepted Russian clinical evidence as sufficient for approval in the US or EU. For research use only; not approved for human consumption outside of Russia. Russian clinical approval status does not substitute for Western regulatory approval. The regulatory pathway remains under active FDA evaluation as of mid-2026.
Research use only. Nothing here is medical or dosing advice.
Semax — FAQ
Is Semax approved by the FDA?
Not currently. Semax is scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026, but is not yet FDA-approved in the United States. It is approved and clinically used in Russia since 1994 for stroke recovery and cognitive disorders, but Russian approval does not equal US FDA approval.
How does Semax work?
Semax is an ACTH(4-10) analog that upregulates two neurotrophic factors simultaneously: BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor). This dual upregulation is uncommon and may explain its broad cognitive effects. A single dose triples hippocampal BDNF expression.
What are the cognitive benefits of Semax?
Research shows improvements in attention span, memory formation, information processing speed, and learning capacity. In Russian clinical trials, intranasal Semax improved work efficiency in operators and showed potential benefits in stroke recovery, cognitive decline, and preliminary evidence in Alzheimer's disease models.
What are the side effects of Semax?
In Russian clinical use, side effects are mild and include nasal irritation (when administered intranasally), headache, and occasional overstimulation in sensitive individuals. Serious adverse effects are rare, and no dependence or withdrawal has been reported. However, formal Western safety studies are absent.
See which vendors pass our audit for Semax.
Why trust this comparison
- Every vendor is scored from real evidence on four public, weighted axes — before we know any margins.
- Purity claims are cross-checked against named third-party labs (MZ Biolabs, Finnrick, Janoshik). Claim-only purity is marked as such.
- The scoring code can't read which vendor pays us — the editorial-commerce firewall is enforced in software.
- We disclose the 20% / 10% Alpha Pro commission on every page, above the first link.
Vendors out-rank our own partner: Peptide Partners (9.0) and Protide Health (8.9) and Ascension Peptides (8.8) both score above Alpha Pro (8.6). We left it that way.